(CercleFinance.com) – OSE Immunotherapeutics announces that it has presented a positive interim analysis of data from the phase 1/2 clinical trial relating to the first use in kidney transplantation of the anti-CD28 FR104/VEL-101, carried out with the Nantes University Hospital.
At this interim scan, no security alerts were detected. The adverse effects were those classically observed in kidney transplantation and no acute rejection was observed under FR104/VEL-101.
‘This major step marks a key advance in the clinical development of the CD28 antagonist FR104/VEL-101 towards a phase 2 trial’, specifies Nicolas Poirier, CEO of the biopharmaceutical company.